Core Viewpoint - New peer-reviewed data supports masitinib's potential as a treatment for sporadic Alzheimer's disease through cognitive enhancement and neuroprotection [1][5][6] Group 1: Clinical Evidence - A new study from independent researchers indicates that masitinib improves cognitive functions in a mouse model of sporadic Alzheimer's disease, showing enhancements in memory, learning, and anxiety-like behaviors [3][4] - The study demonstrated that masitinib reduced toxic brain proteins, alleviated synaptic dysfunction, and suppressed microglial activation, which is linked to inflammation in Alzheimer's disease [4][5] - Results from a phase 2B/3 study (AB09004) showed that masitinib treatment significantly reduced cognitive impairment in patients with mild Alzheimer's disease, with a notable improvement in the mild impairment subgroup [8][9] Group 2: Regulatory and Development Status - The FDA and key EU countries have authorized a phase 3 clinical study (AB21004) to evaluate masitinib as a disease-modifying therapy for Alzheimer's disease [10][11] - The phase 3 study aims to confirm previous findings from the phase 2B/3 study regarding masitinib's efficacy in slowing cognitive deterioration and improving daily living activities [12] Group 3: Intellectual Property - AB Science has filed a patent application for masitinib's use in treating Alzheimer's disease, which, if granted, will provide protection until 2041 [13]

Core Insights - Firefly Neuroscience, Inc. has made significant advancements in Alzheimer's research, focusing on differentiating between subjective cognitive decline (SCD), mild cognitive impairment (MCI), and dementia through accessible diagnostic methods [1][2] Group 1: Research Findings - The combination of EEG/ERP and volumetric magnetic resonance imaging (vMRI) provides the most accurate results for diagnosing cognitive impairments, achieving an accuracy of approximately 87% (AUC=0.87) when both methods are used together [2] - Key EEG measures identified include reaction time, commission errors, and P300b amplitude, which alone can categorize subjects with around 80% accuracy (AUC=0.79) [2] - The left temporal lobe size is a significant MRI predictor of cognitive issues, with smaller sizes correlating to higher cognitive impairment [2] Group 2: Company Developments - Firefly's recent acquisition of Evoke Neuroscience has enabled the integration of research teams to leverage a proprietary database of over 180,000 standardized EEG/ERP assessment records [3] - The company is working to link its breakthrough cognitive brain age biomarker with the findings from the recent study, aiming for a proactive approach to early screening and staging of Alzheimer's disease [3] - Firefly's FDA-cleared Brain Network Analytics (BNA™) technology is set to revolutionize diagnostic and treatment monitoring methods for various neurological and mental disorders [4][5] Group 3: Market Position and Strategy - Firefly targets pharmaceutical companies involved in drug research and clinical trials, as well as medical practitioners for clinical use of its BNA™ technology [4] - The company has built a comprehensive database of brain wave tests over the past 15 years, securing patent protection and achieving FDA clearance for its technologies [4][5]

NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today is joining with the Alzheimer’s disease advocacy community to raise awareness of the growing impact of Alzheimer’s disease in the United States and the importance of brain health during this year’s Alzheimer’s & Brain Awareness Month. “Alzheimer’s & Brain Awareness Month offers the perfect opportunity for all Ame ...

NASDAQ: LNTH Lantheus Investor Presentation BUILDING ON OUR FOUNDATION TO POWER THE FUTURE OF RADIOPHARMACEUTICALS 2025 Truist Securities MedTech Conference June 17, 2025 © 2025 Lantheus. All rights reserved. Safe Harbor Statements Cautionary Statement Regarding Forward-Looking Statements This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and uncertainties and are made pursuant to the safe harbor ...

[Music] So, these are my favorite pants. Okay, so they were my favorite pants until my mom cut the leg off. See, my mom owned a sewing business on the side.It's called Sue Sews cuz her name is Sue and she sews. I think we can all agree that's pretty adorable. She's been sewing since she was 10 years old.And in a childhood where she wasn't always valued or respected, sewing gave her dignity. It gave her joy. When my sister and I were little, she would sew us these beautiful dresses.And I remember once she se ...

NewAmsterdam Pharma Company (NAMS) 2025 Update / Briefing June 11, 2025 09:00 AM ET Speaker0 Alright. Good morning, everybody. Welcome to New Amsterdam's R and D Day. Thank you for everyone to show up who's live here as well as everyone who's on the webcast. We have a exciting day planned for you. Speaker1 Let's see here. Speaker0 you know, we may be making forward looking statements today, so please everyone pay attention to this slide. So just to kind of give you a brief overview of what will be discussed ...

Welcome to R&D Day June 11, 2025 Disclaimer Forward Looking Statements Certain statements included in this presentation (together with oral statements made in connection herewith, this "Presentation") that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," ...

Financial Data and Key Metrics Changes - The company is executing a Fit for Growth program aimed at optimizing its cost structure, with a target of achieving $800 million in net cost savings by the end of the year [44] - The company has successfully executed activities necessary to yield $1 billion in growth and $800 million in net savings [44] Business Line Data and Key Metrics Changes - The company has shifted its focus from primarily neuroscience to include immunology and nephrology, with significant investments in four ongoing product launches [4][9] - The company has nine programs in phase three or phase three ready, indicating a robust pipeline for future growth [7] Market Data and Key Metrics Changes - The U.S. launch of Skyclaris is in a steady growth phase, while initial launches in Europe are progressing similarly [48] - The company has received approval in Brazil for Skyclaris, which is expected to be an important market [49] Company Strategy and Development Direction - The company is focused on redeploying capital from its MS business to support new growth opportunities in nephrology and immunology [5] - The company is actively pursuing business development opportunities, including the acquisition of Hai Bio, to enhance its pipeline [7][8] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the foundational position of the company for future capital deployment and growth opportunities [6] - The company is monitoring potential changes in drug pricing policies and tariffs, which could impact negotiations in the EU [14][15] Other Important Information - The company is excited about the potential of its pipeline assets, particularly in rare diseases and kidney diseases, as highlighted in an upcoming investor presentation [40][41] - The company is leveraging AI technology to identify patients for its therapies, indicating a focus on innovative approaches in patient engagement [49] Q&A Session Summary Question: How is the firm balanced now in terms of various disease areas? - The company is leveraging existing expertise in rare diseases while expanding into nephrology and immunology through strategic acquisitions [10] Question: What is the comfort level among PCP providers with the use of blood-based biomarker tests for Alzheimer's? - PCP providers are already using blood-based biomarkers alongside PET scans, indicating a growing acceptance of these tests [26] Question: What are the expectations for the upcoming readouts from the company's trials? - The company anticipates steady progression in growth and is optimistic about the potential for inflection points with new diagnostic tests and treatment methods [27]

Core Viewpoint - Sanofi has agreed to acquire Vigil Neuroscience for approximately $470 million, enhancing its neurology pipeline with the addition of VG-3927, an investigational treatment for Alzheimer's disease [1][4]. Group 1: Acquisition Details - The acquisition involves Sanofi purchasing all outstanding shares of Vigil at $8 per share in cash, with Vigil shareholders also eligible for a contingent value right of $2 per share upon the first sale of VG-3927 [3]. - The transaction is expected to close in the third quarter of 2025, subject to customary closing conditions, and will not affect Sanofi's financial guidance for 2025 [4]. Group 2: Product Information - VG-3927 is a TREM2 agonist aimed at enhancing the neuroprotective function of microglia in Alzheimer's patients, differing from existing FDA-approved drugs that target amyloid beta plaque accumulation [2][8]. - Sanofi is not acquiring Vigil's other candidate, iluzanebart (VGL101), which is in mid-stage development for a rare neurodegenerative disease [5]. Group 3: Market Context - Year-to-date, Sanofi's shares have increased by 9.7%, contrasting with a 3.9% decline in the industry [2]. - Currently, there are two FDA-approved drugs for Alzheimer's disease: Biogen's Leqembi and Eli Lilly's Kisunla, both targeting amyloid beta accumulation [8][9].

Alpha Cognition (NASDAQ: ACOG ) is an relatively unknown pharmaceutical company that just launched its first commercial product, Zunveyl (benzgalantamine), in March for the symptomatic treatment of mild-to-moderate Alzheimer’s disease (AD). After receiving FDA approval in July 2024, Alpha Cognition quietlyAnalyst’s Disclosure: I/we have a beneficial long position in the shares of ACOG either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions ...